SignalEarnings
Revolution Medicines posted $198M in Q3 revenue, but that reflects about five weeks of RASONQUE plus EAP patient transitions and initial channel stocking, which management flagged as finite early-laun
Revolution Medicines posted $198M in Q3 revenue, but that reflects about five weeks of RASONQUE plus EAP patient transitions and initial channel stocking, which management flagged as finite early-laun
What changed
Revolution Medicines posted $198M in Q3 revenue, but that reflects about five weeks of RASONQUE plus EAP patient transitions and initial channel stocking, which management flagged as finite early-laun
Why it matters
Revolution Medicines posted $198M in Q3 revenue, but that reflects about five weeks of RASONQUE plus EAP patient transitions and initial channel stocking, which management flagged as finite early-laun — impact context not separately stored; see What changed.